AIMS: To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies. DESIGN: Double-blind pharmacogenetic efficacy trials randomizing participants to active or placebo bupropion. Study 1 also randomized participants to cognitive-behavioral smoking cessation treatment (CBT) or this treatment with CBT for depression. Study 2 provided standardized behavioural support. SETTING:Two hospital-affiliated clinics (study 1), and two university-affiliated clinics (study 2). PARTICIPANTS: A total of 792 self-identified white treatment-seeking smokers aged ≥18 years smoking ≥10 cigarettes per day over the last year. MEASUREMENTS: Age, gender, Fagerström Test for Nicotine Dependence, dopamine pathway genotypes (rs1800497 [ANKK1 E713K], rs4680 [COMT V158M], DRD4 exon 3 variable number of tandem repeats polymorphism [DRD4 VNTR], SLC6A3,3' VNTR) analyzed both separately and as part of an AGES, time to first lapse and point prevalence abstinence at end of treatment. FINDINGS: Significant associations of the AGES (hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 1.06-1.14, P = 0.009) and of the DRD4 VNTR (HR = 1.29, 95% CI = 1.17-1.41, P = 0.0073) were observed with time to first lapse. A significant AGES by pharmacotherapy interaction was observed (β standard error = -0.18 [0.07], P = 0.016), such that AGES predicted risk for time to first lapse only for individuals randomized to placebo. CONCLUSIONS: A score based on functional polymorphisms relating to dopamine pathways appears to predict lapse to smoking following a quit attempt, and the association is mitigated in smokers using bupropion.
RCT Entities:
AIMS: To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies. DESIGN: Double-blind pharmacogenetic efficacy trials randomizing participants to active or placebo bupropion. Study 1 also randomized participants to cognitive-behavioral smoking cessation treatment (CBT) or this treatment with CBT for depression. Study 2 provided standardized behavioural support. SETTING: Two hospital-affiliated clinics (study 1), and two university-affiliated clinics (study 2). PARTICIPANTS: A total of 792 self-identified white treatment-seeking smokers aged ≥18 years smoking ≥10 cigarettes per day over the last year. MEASUREMENTS: Age, gender, Fagerström Test for Nicotine Dependence, dopamine pathway genotypes (rs1800497 [ANKK1 E713K], rs4680 [COMT V158M], DRD4 exon 3 variable number of tandem repeats polymorphism [DRD4 VNTR], SLC6A3,3' VNTR) analyzed both separately and as part of an AGES, time to first lapse and point prevalence abstinence at end of treatment. FINDINGS: Significant associations of the AGES (hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 1.06-1.14, P = 0.009) and of the DRD4 VNTR (HR = 1.29, 95% CI = 1.17-1.41, P = 0.0073) were observed with time to first lapse. A significant AGES by pharmacotherapy interaction was observed (β standard error = -0.18 [0.07], P = 0.016), such that AGES predicted risk for time to first lapse only for individuals randomized to placebo. CONCLUSIONS: A score based on functional polymorphisms relating to dopamine pathways appears to predict lapse to smoking following a quit attempt, and the association is mitigated in smokers using bupropion.
Authors: Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut Journal: Am J Psychiatry Date: 2012-07 Impact factor: 18.112
Authors: Saul Shiffman; Deborah M Scharf; William G Shadel; Chad J Gwaltney; Qianyu Dang; Stephanie M Paton; Duncan B Clark Journal: J Consult Clin Psychol Date: 2006-04
Authors: Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Alan F Schatzberg; Greer M Murphy Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-01-25 Impact factor: 3.568
Authors: Andrew W Bergen; Harold S Javitz; Li Su; Yungang He; David V Conti; Neal L Benowitz; Rachel F Tyndale; Caryn Lerman; Gary E Swan Journal: Nicotine Tob Res Date: 2012-12-03 Impact factor: 4.244
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Naji C Salloum; Erica L F Buchalter; Swati Chanani; Gemma Espejo; Mahjabeen S Ismail; Randy O Laine; Maysaa Nageeb; A Benjamin Srivastava; Nicholas Trapp; Ludwig Trillo; Erica Vance; Michael Wenzinger; Sarah M Hartz; Sean P David; Li-Shiun Chen Journal: Pharmacogenomics Date: 2018-06-19 Impact factor: 2.533
Authors: Fatemeh Noohi; Nate B Boyden; Youngbin Kwak; Jennifer Humfleet; Martijn L T M Müller; Nicolaas I Bohnen; Rachael D Seidler Journal: Neuropsychologia Date: 2016-02-27 Impact factor: 3.139
Authors: Li-Shiun Chen; Timothy B Baker; Douglas Jorenby; Megan Piper; Nancy Saccone; Eric Johnson; Naomi Breslau; Dorothy Hatsukami; Robert M Carney; Laura J Bierut Journal: Drug Alcohol Depend Date: 2015-06-23 Impact factor: 4.492
Authors: Li-Shiun Chen; Laurie Zawertailo; Thomas M Piasecki; Jaakko Kaprio; Marilyn Foreman; Hannah R Elliott; Sean P David; Andrew W Bergen; James W Baurley; Rachel F Tyndale; Timothy B Baker; Laura J Bierut; Nancy L Saccone Journal: Nicotine Tob Res Date: 2018-03-06 Impact factor: 4.244
Authors: Ewoud Schuit; Orestis A Panagiotou; Marcus R Munafò; Derrick A Bennett; Andrew W Bergen; Sean P David Journal: Cochrane Database Syst Rev Date: 2017-09-08